Lucon Biopharmaceutical

Hangzhou Lucon Biopharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, that focuses on the discovery and development of innovative antibody-based therapeutics for oncology. The company leverages proprietary platforms to design multi-functional antibodies and next-generation antibody-drug conjugates (ADCs) aimed at addressing unmet needs in cancer immunotherapy. Its lead candidate, LC001, is a PD-L1/TGF-beta bifunctional fusion protein currently being evaluated in Phase 2 trials for various advanced solid tumors. Additionally, the company is advancing a pipeline of bispecific antibodies and ADCs, including LC002, a Claudin 18.2-targeted ADC, through clinical development. Backed by prominent venture capital firms, Lucon Biopharm strives to provide transformative treatment options for patients with refractory or resistant cancers.